Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking back to voices: CBT shows promise for schizophrenia hallucinations

NCT ID NCT07524868

Symptom relief Sponsor: Hasanuddin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding cognitive behavioral therapy (CBT) to standard medication (risperidone) could reduce auditory hallucinations and inflammation in 50 people with schizophrenia. Participants either received CBT plus medication or medication alone. The goal was to see if CBT helps with distressing voices and lowers a blood marker of inflammation called NLR.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cognitive Behavioral Therapy (CBT)
What this could lead to
If it works, this could point toward a way to ease distressing voices and reduce inflammation in people with schizophrenia who still hear voices despite medication.
What could go wrong
This is a small, completed study with only 50 people, so results may not apply to everyone. CBT requires time and effort, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Nov 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with schizophrenia based on clinical assessment * Age 18-60 years * Experiencing auditory hallucinations * Currently receiving antipsychotic treatment (e.g., risperidone) * Able to communicate and participate in Cognitive Behavioral Therapy (CBT) * Willing to provide informed consent Exclusion Criteria: * Presence of severe medical or neurological illness * Substance use disorder (excluding nicotine) * Severe cognitive impairment or inability to participate in interviews * Patients with acute agitation or requiring emergency intervention * Currently receiving structured psychotherapy other than CBT

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Auditory hallucination are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hallucinations Inflammation schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Auditory hallucination Schizophrenia patients

Contacts and locations

Locations

  • Regional Special Hospital (RSKD) Dadi, South Sulawesi, Indonesia

    Makassar, South Sulawesi, 90245, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.